We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CDE

News List

Update on Priority Review by CDE: Acceptance of First CAR-T Therapy Clinical Application cccmhpie
February 02, 2018
On December 11, 2017, the first CAR-T project clinical application in China (CXSL1700201) filed by Nanjing Legend Biotechnology Co., Ltd. (hereinafter referred to as Nanjing Legend) was formally undertaken and accepted by the CDE
Update on Priority Review by CDE: Biggest Bright Spot Being the Inclusion of Novartis’ LCZ696 cccmhpie
January 31, 2018
CDE publicized on December 2 the twelfth batch of registration applications of pharmaceutical products to be included in the priority review procedure, with 32 acceptance numbers in total included in the list.
“BioTaiwan, China's growth is a reflection of the success of Taiwan, China biotech as a whole in recent years.” biospectrumasia
August 10, 2017
BioSpectrum Asia recently spoke to Dr Apo Huang, Secretary General, BioTaiwan, China on the current growth in the Taiwan, Chinaese biotech sector.
Analysis of the Policy Signals in the 2016 Drug Review Annual Report of CDE en-cphi.cn
March 31, 2017
CDE (Center for Drug Evaluation, CFDA) issued 2016 Drug Review Annual Report on March 17, 2017.

Previous page 1 2 Next page